Furthermore, the beneficial metabolic and antidiabetic effects of TAAR1 agonists raise the question of whether these agents may be uniquely positioned to improve comorbid metabolic disorders in patients with schizophrenia. The gene discussed is TAAR1; the disease is schizophrenia.